Sodium lauryl sulfate
As of the edition of 20 October 2026, Sodium lauryl sulfate is a small molecule: marketed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Small molecule
- Brand name
- Anticerumen Liade
- Approvals on record
- 4 in 4 regions
- Holder of the most recent approval
- Arkomedica; 4 holders in all
- Registered trials
- 5, 0 stopped early
- Disease areas
- Bones, joints and muscles; Injuries
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Dr. Reddy's | Lead sponsor of trials | 2014 to now |
| Almirall | Lead sponsor of trials | 2014 to now |
| Biosplice Therapeutics | Lead sponsor of trials | 2017 to now |